Compare Mesoblast Limited (MESO) vs PepsiCo, Inc. (PEP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs PepsiCo, Inc. — how do they compare? Mesoblast Limited trades at $16.38 (market cap $2.17B), while PepsiCo, Inc. trades at $135.13 (market cap $184.89B). The key difference: PepsiCo, Inc. is far larger — about 85.2× Mesoblast Limited's market cap, and PepsiCo, Inc. pays a 4.37% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MESO | PEP | |
|---|---|---|
Market Cap | $2.17B | $184.89B |
Sector | Technology | Consumer Staples |
52-Week High | $20.96 | $170.44 |
52-Week Low | $12.88 | $135.40 |
Enterprise Value | $2.17B | $227.39B |
Dividend Yield | — | 4.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $36 million for Ryoncil, showing strong commercial progress, but maintains a net income margin of -144.33% with significant losses. Recent news highlights pivotal Phase 3 trial milestones for chronic low back pain treatment and a $50 million non-dilutive financing draw.
Outlook is mixed: bullish analyst sentiment and clinical advancements offer upside potential, but high cash burn and persistent losses pose substantial risks. Investors should weigh the company's growth trajectory against its financial sustainability and regulatory milestones.
PepsiCo (PEP) trades at $134.98, down 1.56% today, with a bearish technical signal as moving averages indicate selling pressure. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue grew to $93.93B in 2025, though net income margin dipped to 8.77%. Analysts maintain a consensus price target of $158.50, implying upside, while recent news highlights price cuts on snacks to address consumer pushback on high costs.
The outlook for PEP is mixed; strong cash flow and dividend payments support income investors, but margin pressure and competitive risks persist. Upside depends on North American performance recovery and effective pricing strategy execution. Key risks include consumer sensitivity to price hikes and macroeconomic headwinds affecting discretionary spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About PepsiCo, Inc.
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →
